The extracellular domain of plasma membrane integrin αvβ3 contains a cell surface receptor
for thyroid hormone analogues. The receptor is largely expressed and activated in tumor …

Tyrosine kinase inhibitors (TKIs) have improved outcome for many tumors. Although better
tolerated than cytotoxic chemotherapy, they may cause several adverse events (AEs) and …

Sunitinib is a potent anti-cancer scaffold that acts as a VEGFR-2 inhibitor. Although the
scaffold exhibits potent anti-cancer activity, it is cardiotoxic and also induces hypothyroidism …

Recently, the medications used for the severe form of the coronavirus disease-19 (COVID-
19) therapy are of particular interest. In this sense, it has been supposed that anti-VEGF …

Background and purpose Immune checkpoint inhibitors (ICIs) are monoclonal antibodies
that enhance the immune response against cancer cells. ICIs are generally well tolerated …

The increasing knowledge of the molecular mechanisms in the cell signaling pathways of
malignant cells, has recently led to the discovery of several tyrosine kinases (TKs), mainly …

Simple Summary Patients with advanced hepatocellular carcinoma (HCC) undergoing
molecular targeted therapy often experience non-negligible adverse events (AEs) …

Purpose This narrative review aims to summarize the relationship between hyperthyroidism,
upper reference range thyroid hormone (TH) levels, and cancer, and to address the clinical …

Background Conflicting evidence exists regarding the effect of hypertension on the
prognosis of metastatic renal cell carcinoma (mRCC) patients treated with tyrosine kinase …

Background Thyroid hormone impairment, represented as an alteration in levels of thyroid
hormones and a lower fT3/fT4 ratio, has been correlated with a worse prognosis for both …